Merck quarterly profit rises nearly 55% as key drug sales rebound

Credit: REUTERS/Brendan McDermid

Oct 27 (Reuters) - Merck & Co Inc MRK.N on Tuesday reported a 54.7% rise in third-quarter profit, helped by strong sales of blockbuster cancer drug Keytruda and rebound in sales of its key drugs.

The company's net income rose to $2.94 billion, or $1.16 per share, in the third quarter ended Sept. 30, from $1.90 billion, or $0.74 per share, a year earlier.

(Reporting Manojna Maddipatla in Bengaluru; Editing by Shailesh Kuber)

((; +91 8061822700;))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


More Related Articles

Sign up for Smart Investing to get the latest news, strategies and tips to help you invest smarter.